Experimental cell therapy for advanced lung cancer shows early promise but trial halted
NCT ID NCT06491225
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a personalized treatment called GTE-001, which uses immune cells taken from a patient's own tumor to attack their cancer. It was designed for people with advanced lung adenocarcinoma that had stopped responding to standard chemotherapy. However, the study was terminated after enrolling only 2 participants, so we have very limited information about its safety or effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tumor-infiltrating lymphocytes (GTE-001 injection)
- What this could lead to
- If it works, this could point toward a new cell-based treatment for advanced lung adenocarcinoma that has stopped responding to standard chemotherapy.
- What could go wrong
- This was a very early, small trial (only 2 participants) that was terminated, so we have very little data. The approach is complex and may not work for most patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG ADENOCARCINOMA；ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Hospital
Beijing, Beijing Municipality, 102200, China